Cancer therapy-induced cardiotoxicity.
Anthracyclines as doxorubicin remain first line of therapy for many cancer types. Every year, 3 million Europeans receive anthracyclines and that 30% of them will suffer cardiac toxicity. It is estimated that 1 million Europeans live with chronic heart failure secondary to anthracycline’s cardiotoxicity. The main objective of this study is to evaluate doxorubicin accumulation in a translational mice and pig model of Anthracycline-Induced Cardiotoxicity. For that purpose, we will use a wide variety of complementary experimental approaches ranging from genetically modified mice to microscopy and molecular techniques (qPCR, Western Blot, Oroboros and others). The present project aims to improve quality of life in cancer survivors identifying potential therapeutic targets to reduce doxorubicin accumulation.
Borja Ibañez, Laura Cádiz.
Correo electrónico: lcadiz@cnic.es.
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC).
Número de plazas ofertadas: 2.
Facultad de Medicina. Universidad Autónoma de Madrid. Calle del Arzobispo Morcillo 4. 28029 Madrid. Tel.: +34 914 975 486. Correo electrónico: informacion.medicina@uam.es
